TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%

TELA Bio, Inc.

Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.
Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.
Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.
Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.
U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026.

item 2.02item 7.01item 9.01

Source: SEC EDGAR

accession 0001104659-26-059393

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.